دورية أكاديمية
أعرض في EDS

Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.

التفاصيل البيبلوغرافية
العنوان: Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
المؤلفون: Walma MS; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Brada LJ; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Patuleia SIS; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Blomjous JG; Dept. of Radiology, OLVG, Amsterdam, the Netherlands., Bollen TL; Dept. of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Bosscha K; Dept. of Surgery, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Bruijnen RC; Dept. of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Busch OR; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Creemers GJ; Dept. of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Daams F; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Dam R; Dept. of Surgery, Maastricht UMC+, Maastricht, the Netherlands., Festen S; Dept. of Surgery, OLVG, Amsterdam, the Netherlands., Jan de Groot D; Dept. of Medical Oncology, UMC Groningen, Groningen, the Netherlands., Willem de Groot J; Dept. of Medical Oncology, Isala Clinics, Zwolle, the Netherlands., Mohammad NH; Dept. of Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Hermans JJ; Dept. of Radiology, Radboud University Medical Center, Nijmegen, the Netherlands., de Hingh IH; Dept. of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Kerver ED; Dept. of Medical Oncology, OLVG, Amsterdam, the Netherlands., van Leeuwen MS; Dept. of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., van der Leij C; Dept. of Radiology, Maastricht UMC+, Maastricht, the Netherlands., Liem MS; Dept. of Surgery, Medical Spectrum Twente, Enschede, the Netherlands., van Lienden KP; Dept. of Radiology Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amstrdam, the Netherlands., Los M; Dept. of Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., de Meijer VE; Dept. of Surgery, UMC Groningen, Groningen, the Netherlands., Meijerink MR; Dept. of Radiology Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amstrdam, the Netherlands., Mekenkamp LJ; Dept. of Medical Oncology, Medical Spectrum Twente, Enschede, the Netherlands., Nederend J; Dept. of Radiology, Catharina Hospital, Eindhoven, the Netherlands., Nio CY; Dept. of Radiology Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amstrdam, the Netherlands., Patijn GA; Dept. of Surgery, Isala Clinics, Zwolle, the Netherlands., Polée MB; Dept. of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Pruijt JF; Dept. of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Renken NS; Dept. of Radiology, Reinier de Graaf Hospital, Delft, the Netherlands., Rombouts SJ; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Schouten TJ; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Stommel MWJ; Dept. of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Verweij ME; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., de Vos-Geelen J; Dept. of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands., de Vries JJJ; Dept. of Radiology Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amstrdam, the Netherlands., Vulink A; Dept. of Medical Oncology, Reinier de Graaf Hospital, Delft, the Netherlands., Wessels FJ; Dept. of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Wilmink JW; Dept. of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam; the Netherlands., van Santvoort HC; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., Besselink MG; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: m.g.besselink@amc.nl., Molenaar IQ; Dept. of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands.
مؤلفون مشاركون: Dutch Pancreatic Cancer Group
المصدر: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Mar; Vol. 47 (3 Pt B), pp. 699-707. Date of Electronic Publication: 2020 Nov 26.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8504356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2157 (Electronic) Linking ISSN: 07487983 NLM ISO Abbreviation: Eur J Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: : Amsterdam : Elsevier
Original Publication: London ; New York : Academic Press, [1985-
مواضيع طبية MeSH: Pancreatectomy*, Adenocarcinoma/*therapy , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Pancreatic Neoplasms/*therapy, Adenocarcinoma/pathology ; Aged ; Albumins/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Cohort Studies ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoadjuvant Therapy ; Oxaliplatin/therapeutic use ; Paclitaxel/administration & dosage ; Pancreatic Neoplasms/pathology ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Survival Rate ; Gemcitabine
مستخلص: Introduction: Since current studies on locally advanced pancreatic cancer (LAPC) mainly report from single, high-volume centers, it is unclear if outcomes can be translated to daily clinical practice. This study provides treatment strategies and clinical outcomes within a multicenter cohort of unselected patients with LAPC.
Materials and Methods: Consecutive patients with LAPC according to Dutch Pancreatic Cancer Group criteria, were prospectively included in 14 centers from April 2015 until December 2017. A centralized expert panel reviewed response according to RECIST v1.1 and potential surgical resectability. Primary outcome was median overall survival (mOS), stratified for primary treatment strategy.
Results: Overall, 422 patients were included, of whom 77% (n = 326) received chemotherapy. The majority started with FOLFIRINOX (77%, 252/326) with a median of six cycles (IQR 4-10). Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3-5) and three (IQR 3-5) cycles respectively. The mOS of the entire cohort was 10 months (95%CI 9-11). In patients treated with FOLFIRINOX, gemcitabine monotherapy, or nab-paclitaxel/gemcitabine, mOS was 14 (95%CI 13-15), 9 (95%CI 8-10), and 9 months (95%CI 8-10), respectively. A resection was performed in 13% (32/252) of patients after FOLFIRINOX, resulting in a mOS of 23 months (95%CI 12-34).
Conclusion: This multicenter unselected cohort of patients with LAPC resulted in a 14 month mOS and a 13% resection rate after FOLFIRINOX. These data put previous results in perspective, enable us to inform patients with more accurate survival numbers and will support decision-making in clinical practice.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: FOLFIRINOX; Locally advanced pancreatic cancer; Treatment strategies
المشرفين على المادة: 0 (130-nm albumin-bound paclitaxel)
0 (Albumins)
0 (Antimetabolites, Antineoplastic)
0 (folfirinox)
04ZR38536J (Oxaliplatin)
0W860991D6 (Deoxycytidine)
7673326042 (Irinotecan)
P88XT4IS4D (Paclitaxel)
Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
0 (Gemcitabine)
تواريخ الأحداث: Date Created: 20201207 Date Completed: 20210914 Latest Revision: 20221207
رمز التحديث: 20221213
DOI: 10.1016/j.ejso.2020.11.137
PMID: 33280952
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-2157
DOI:10.1016/j.ejso.2020.11.137